SDMA is cleared almost exclusively by the kidneys, so reducing SDMA requires improving or preserving kidney function. Interventions include aggressive blood pressure management (the most impactful for CKD progression), blood sugar control in diabetic kidney disease, reduction of proteinuria (ACE inhibitors or ARBs), dietary protein optimization (not excessive, not severely restricted), adequate hydration, avoidance of nephrotoxic agents (NSAIDs, contrast agents, aminoglycosides), and aggressive management of all cardiovascular risk factors. L-arginine supplementation may partially compete with SDMA at the NOS enzyme but does not address the underlying kidney function decline.

Lab Reference Library / SDMA (Symmetric Dimethylarginine) Liver & Kidney

SDMA (Symmetric Dimethylarginine)

SDMA · Symmetric Dimethylarginine

Reference range, optimal functional medicine levels, and why SDMA is the most sensitive early kidney biomarker available, detecting glomerular filtration decline before creatinine, cystatin C, or eGFR become abnormal, and independently predicting cardiovascular mortality through nitric oxide pathway disruption.

Kidney MarkerEarly Detection

Standard RangeBelow 0.70 mcmol/L

FM OptimalBelow 0.50 mcmol/L

SensitivityDetects 25% GFR loss

Unitsmcmol/L

← Back to Lab Reference Library

Category: Liver & Kidney | Also known as: Symmetric Dimethylarginine, Serum SDMA | Sample: Serum (fasting not required; consistent conditions improve trend tracking)

1. What This Test Measures

SDMA (Symmetric Dimethylarginine) is a naturally occurring methylated arginine derivative produced when arginine residues in proteins are post-translationally methylated by protein arginine methyltransferase (PRMT) enzymes. As proteins are degraded during normal cellular turnover, methylated arginine residues are released as free SDMA into the bloodstream. Unlike standard arginine, methylated arginine residues cannot be recycled into new proteins and must be excreted as SDMA.

SDMA has three critical properties that make it the most sensitive early kidney biomarker available:

Exclusive renal excretion: SDMA is cleared almost entirely by the kidneys through glomerular filtration, with essentially no tubular secretion or reabsorption and no significant non-renal clearance pathways. This makes rising serum SDMA almost exclusively reflective of declining glomerular filtration.
Constant production independent of muscle mass: like cystatin C, SDMA production is driven by normal protein turnover throughout all tissues, not proportional to muscle mass. This makes it reliable across all body compositions without the sarcopenia and muscle mass confounders that limit creatinine.
Superior sensitivity for early decline: SDMA rises detectably when GFR has declined by approximately 25%, compared to creatinine which does not rise detectably until 50 to 60% of GFR is lost. This window represents 1 to 2 years of additional lead time for intervention in many patients with progressive CKD.

SDMA is not only a kidney function marker; it is also a direct mediator of vascular disease through nitric oxide pathway disruption, making elevated SDMA simultaneously a kidney health and cardiovascular risk biomarker.

2. SDMA and the Nitric Oxide Connection

SDMA is a competitive inhibitor of all three isoforms of nitric oxide synthase (NOS), the enzyme family that produces nitric oxide (NO) from the substrate L-arginine. Nitric oxide is the primary endothelium-derived vasodilator, anti-platelet agent, and endothelial protectant in the cardiovascular system. When SDMA accumulates from kidney function decline, it directly impairs nitric oxide production through competitive inhibition at the NOS enzyme.

The cardiovascular consequence: reduced nitric oxide from SDMA accumulation causes endothelial dysfunction (impaired vasodilation), increased platelet aggregation, upregulation of adhesion molecules (VCAM-1, ICAM-1), and promotion of vascular smooth muscle proliferation. These are the molecular steps of accelerated atherosclerosis. This mechanism directly explains why CKD is such a powerful independent cardiovascular risk factor: SDMA accumulation from even mild kidney function decline begins impairing endothelial nitric oxide production long before conventional kidney markers become abnormal.

Note: SDMA is the symmetric isomer of dimethylarginine. Its asymmetric counterpart, ADMA (asymmetric dimethylarginine), is the more potent NOS inhibitor and the more established cardiovascular risk biomarker, though SDMA's exclusive renal excretion makes it the more specific kidney function marker of the two.

3. Standard Lab Reference Range

SDMA Level	Classification
Below 0.70 mcmol/L	Standard reference range upper limit (adult)
0.50 to 0.70 mcmol/L	Borderline functional medicine range; monitor closely
Above 0.70 mcmol/L	Elevated: reduced kidney filtration confirmed; evaluate full kidney panel

SDMA is not yet universally available on standard metabolic panels and may require specific ordering at reference laboratories. Its availability is expanding as clinical awareness of its utility grows. Some laboratories report in different units (nmol/L): 0.70 mcmol/L equals 700 nmol/L. The functional medicine optimal is below 0.50 mcmol/L (500 nmol/L).

4. Optimal Functional Medicine Range

SDMA Level	Functional Interpretation
Below 0.40 mcmol/L	Excellent: minimal nitric oxide pathway impairment; optimal kidney filtration
0.40 to 0.50 mcmol/L	Optimal: adequate kidney filtration; low endothelial risk
0.50 to 0.60 mcmol/L	Borderline: earliest kidney decline signal; address risk factors; check urine ACR; 6-month recheck
0.60 to 0.70 mcmol/L	Elevated (pre-threshold): meaningful decline; correlate with cystatin C; aggressive risk management
Above 0.70 mcmol/L	Elevated: significant filtration impairment; full kidney panel; nephrology consultation if progressing

5. Why SDMA Detects Kidney Disease Earlier Than Creatinine

The graphic below conceptually illustrates the detection timeline for each kidney marker as GFR progressively declines from 130 mL/min (young adult) to kidney failure:

GFR Level	SDMA	Cystatin C	Creatinine eGFR	Symptoms
120 to 130 mL/min (normal)	Below 0.50	Below 0.90	Above 90 (normal)	None
95 to 100 mL/min (25% loss)	0.50 to 0.60 (RISING)	0.90 to 1.00 (borderline)	Above 90 (still normal)	None
75 to 85 mL/min (40% loss)	0.60 to 0.70 (elevated)	1.00 to 1.15 (elevated)	75 to 85 (borderline)	Still none
52 to 60 mL/min (50 to 60% loss)	0.70 to 0.90	Above 1.15	Below 60 (NOW DETECTED)	Mild fatigue possible
30 to 45 mL/min (70% loss)	Above 0.90	Above 1.30	45 to 59 (Stage 3a/3b)	Symptoms emerging

The 25% GFR loss threshold at which SDMA becomes detectable represents an opportunity window of approximately 1 to 3 years before creatinine-based eGFR crosses the CKD diagnostic threshold of 60 mL/min. This is the intervention window where lifestyle changes, blood pressure control, and SGLT2 inhibitors have the greatest potential impact on slowing progression.

6. What Causes Elevated SDMA

Reduced GFR from any cause: the primary and most clinically significant driver; CKD from diabetes, hypertension, glomerulonephritis, or other causes accumulates SDMA proportional to filtration loss; SDMA rises earlier than creatinine in all these conditions
Aging: eGFR declines approximately 1 mL/min per year after age 40; SDMA rises progressively with age-related nephron loss; higher SDMA in older adults reflects genuine functional decline, not an artifact
Acute kidney injury: SDMA rises rapidly with acute GFR reduction from sepsis, ischemia, contrast nephropathy, or other AKI causes; may rise within hours of the insult
Hypertension: chronically elevated blood pressure reduces GFR through afferent arteriolar injury; SDMA rises in proportion to GFR loss
Diabetes: hyperglycemia damages glomerular basement membrane and promotes hyperfiltration followed by progressive nephron loss; SDMA rises before creatinine in diabetic nephropathy
NSAID use: reduces prostaglandin-mediated GFR support; chronic NSAID use produces SDMA elevation from reduced functional GFR
Dehydration: acute GFR reduction from dehydration transiently raises SDMA alongside BUN; normalizes with hydration

7. How to Lower SDMA

Kidney Protection

Blood pressure control: the single most impactful intervention for slowing GFR decline and thus SDMA accumulation; target below 130/80 mmHg; below 120/80 mmHg with proteinuria; ACE inhibitors and ARBs are preferred for their antiproteinuric and renoprotective effects
SGLT2 inhibitors (empagliflozin, dapagliflozin): reduce glomerular hyperfiltration through tubuloglomerular feedback; slow eGFR decline in CKD; expected to reduce SDMA as GFR is preserved
Blood sugar control: HbA1c below 7% for diabetic nephropathy; reduce hyperfiltration injury
Adequate hydration: 2 to 3 liters of water daily; prevents dehydration-related transient SDMA elevation
Eliminate NSAIDs: direct reduction of prostaglandin-mediated GFR impairment; switch to acetaminophen or non-pharmacological approaches

Nitric Oxide Support

L-arginine supplementation: the substrate for nitric oxide synthase; by supplementing L-arginine, the competitive inhibition by SDMA at the NOS enzyme is partially overcome; 3 to 6g daily; most effective when SDMA is mildly to moderately elevated and kidney disease is being actively managed
L-citrulline: converts to arginine in the kidney; more bioavailable than arginine supplementation; 3 to 6g daily; raises plasma arginine levels and supports nitric oxide production
Dietary nitrate (beet root juice, leafy greens): provides an arginine-independent pathway to nitric oxide via nitrate reduction; 500mL beet root juice or high-dose greens daily; well-studied for blood pressure and endothelial function
PDE5 inhibitors (tadalafil, sildenafil): potentiate nitric oxide signaling by preventing cGMP degradation; emerging evidence for kidney protection in CKD through reduced glomerular pressure

Nutritional and Lifestyle

Omega-3 fatty acids (2 to 4g EPA and DHA daily): reduce glomerular inflammation and slow CKD progression in inflammatory nephropathies; also support endothelial nitric oxide through AMPK activation
Uric acid management (target below 5.5 mg/dL): hyperuricemia promotes afferent arteriolar vasoconstriction and tubulointerstitial nephritis; reducing uric acid protects GFR and lowers SDMA
Sodium restriction (below 2,000mg daily): reduces glomerular hypertension and proteinuria; preserves GFR and slows SDMA accumulation
Weight loss: reduces glomerular hyperfiltration from obesity; losing even 5 to 10% body weight reduces glomerular pressure and slows nephron loss
Smoking cessation: nicotine causes renal vasoconstriction and independently accelerates CKD; cessation slows GFR decline and reduces SDMA

8. The Complete Kidney Panel: Pattern Interpretation

SDMA is most clinically valuable when it rises before other kidney markers, revealing what creatinine and eGFR are missing:

SDMA	Creatinine eGFR	Cystatin C	Interpretation	Action
Below 0.50	Above 90	Below 0.90	No kidney concern; complete normal panel	Annual monitoring; manage metabolic risk
0.50 to 0.60	Above 90	0.90 to 1.00	Earliest detectable nephron loss; creatinine eGFR not yet affected	Aggressive risk factor management; 6-month recheck; urine ACR
0.60 to 0.70	75 to 89	1.00 to 1.10	Early CKD Stage 2; SDMA and CysC concordant; meaningful decline	Blood pressure, SGLT2i, nephrology awareness
Above 0.70	Below 60	Above 1.15	CKD Stage 3 or above; all markers agree; cardiovascular risk very high	Nephrology referral; intensified cardiovascular management
Above 0.60	Above 90	Below 0.90	Possible early SDMA rise in muscular patient or early nitric oxide impairment; recheck with urine ACR and blood pressure	Repeat in 3 months; check urine ACR

9. Related Lab Tests

Cystatin CSecond Most Sensitive Early Kidney Marker

→

eGFRPrimary CKD Staging Tool

→

CreatinineStandard Kidney Marker; SDMA Precedes It

→

BUNUrea Clearance Companion Marker

→

Uric AcidConcurrent Vascular and Kidney Risk

→

HbA1cDiabetes Management to Protect Kidney GFR

→

10. When Testing Is Recommended

Longevity and biological age panels: SDMA is one of the most sensitive markers of silent kidney aging and cardiovascular risk
Diabetes and hypertension: annual SDMA testing enables earlier CKD detection than creatinine and eGFR alone
Patients with cardiovascular disease: SDMA adds independent kidney-mediated cardiovascular risk assessment
eGFR 75 to 90 mL/min: SDMA identifies whether this represents genuine early decline or body composition artifact
Family history of CKD: SDMA enables proactive monitoring before conventional markers become abnormal
Any patient on chronic NSAIDs: detect subclinical GFR impairment before creatinine rises
Post-AKI monitoring: SDMA confirms recovery of filtration function after an acute kidney injury episode
Hypertension management: SDMA provides early feedback on whether blood pressure control is protecting kidney filtration

11. Clinical Perspective

Clinical Perspective

SDMA is the kidney marker that gives me the earliest clinical intelligence available, and the nitric oxide story is what makes it uniquely important beyond kidney function. When I see SDMA of 0.58 in a 52-year-old with hypertension whose creatinine eGFR is 88, I know three things simultaneously: first, their kidneys have lost more filtration capacity than the creatinine is acknowledging; second, SDMA is already beginning to compete with arginine at the nitric oxide synthase enzyme, reducing endothelial nitric oxide and contributing to their vascular disease; and third, we have a therapeutic window of potentially 2 to 3 years to aggressively protect kidney function before creatinine and eGFR begin to reflect what SDMA is already telling me. That window is everything. That is when blood pressure below 130/80 mmHg, an SGLT2 inhibitor, and NSAID elimination make the largest difference in long-term trajectory. SDMA is the earliest warning we have, and it is actionable.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

12. Frequently Asked Questions

What is SDMA and why is it important?

SDMA (Symmetric Dimethylarginine) is a methylated arginine metabolite cleared almost exclusively by the kidneys. It is the most sensitive standard marker for early kidney function decline, rising when GFR has fallen by approximately 25%, while creatinine does not detectably rise until 50 to 60% of GFR is lost. SDMA is also a competitive inhibitor of nitric oxide synthase, directly impairing endothelial nitric oxide production and contributing to vascular dysfunction.

What is the optimal SDMA level?

In functional medicine, optimal SDMA is below 0.50 mcmol/L. The standard upper reference limit is typically 0.70 mcmol/L, but functional medicine targets the lower portion of the range where nitric oxide synthesis is not yet meaningfully impaired. Any SDMA above 0.50 mcmol/L warrants evaluation of kidney function trends alongside cystatin C, urine albumin/creatinine ratio, and blood pressure.

How does SDMA compare to creatinine?

SDMA detects kidney function decline earlier than creatinine: SDMA rises when approximately 25% of GFR is lost, while creatinine does not rise detectably until 50 to 60% of GFR is lost. SDMA is also not affected by muscle mass, dietary protein, or body composition, making it more reliable across all patient populations. In early stages of kidney disease, SDMA consistently identifies declining function that creatinine-based eGFR misses entirely.

Why does SDMA cause cardiovascular disease?

SDMA competitively inhibits all three isoforms of nitric oxide synthase (eNOS, iNOS, nNOS), the enzyme that produces nitric oxide from arginine. Nitric oxide is the primary endothelium-derived vasodilator and endothelial protectant. When SDMA accumulates from kidney function decline, it directly reduces nitric oxide bioavailability, causing endothelial dysfunction, increased vascular resistance, platelet activation, and accelerated atherosclerosis.

Can SDMA be lowered?

SDMA is cleared almost exclusively by the kidneys, so reducing SDMA requires improving or preserving kidney function through blood pressure control (target below 130/80 mmHg), SGLT2 inhibitors, blood sugar management in diabetic kidney disease, adequate hydration, and elimination of nephrotoxins. L-arginine and L-citrulline supplementation can partially overcome SDMA's NOS inhibition to restore nitric oxide production even while kidney function is being addressed.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

SDMA rises when 25% of your kidney function is gone. Creatinine rises when 50 to 60% is gone. The window in between is where intervention matters most.

Schedule a consultation for a complete kidney panel including SDMA, cystatin C, and urine albumin to detect kidney decline at the earliest actionable stage.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.